Correlation Between Arvinas and Pliant Therapeutics

Can any of the company-specific risk be diversified away by investing in both Arvinas and Pliant Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arvinas and Pliant Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arvinas and Pliant Therapeutics, you can compare the effects of market volatilities on Arvinas and Pliant Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arvinas with a short position of Pliant Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arvinas and Pliant Therapeutics.

Diversification Opportunities for Arvinas and Pliant Therapeutics

0.64

Correlation Coefficient

Arvinas  Pliant Therapeutics

Poor diversification

The 3 months correlation between Arvinas and Pliant is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Arvinas and Pliant Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pliant Therapeutics and Arvinas is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arvinas are associated (or correlated) with Pliant Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pliant Therapeutics has no effect on the direction of Arvinas i.e., Arvinas and Pliant Therapeutics go up and down completely randomly.

Pair Corralation between Arvinas and Pliant Therapeutics

Given the investment horizon of 90 days Arvinas is expected to generate 0.59 times more return on investment than Pliant Therapeutics. However, Arvinas is 1.69 times less risky than Pliant Therapeutics. It trades about -0.14 of its potential returns per unit of risk. Pliant Therapeutics is currently generating about -0.17 per unit of risk. If you would invest  1,900  in Arvinas on December 29, 2024 and sell it today you would lose (1,141) from holding Arvinas or give up 60.05% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Arvinas  vs.  Pliant Therapeutics

Arvinas

Risk-Adjusted Performance

Very Weak

Over the last 90 days Arvinas has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pliant Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pliant Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Arvinas and Pliant Therapeutics

The main advantage of trading using opposite Arvinas and Pliant Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arvinas position performs unexpectedly, Pliant Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pliant Therapeutics will offset losses from the drop in Pliant Therapeutics' long position.

The idea behind Arvinas and Pliant Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.